Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose adjustments, monitoring for gastrointestinal (GI) symptoms, rashes, elevated liver enzymes and glucose metabolism changes, and encouraging patients to maintain ongoing care with their primary care providers for comorbid conditions that could exacerbate potential cardiovascular risks.

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without fasting requirements, can improve the chronic myeloid leukemia (CML) management approach by making medication adherence easier for patients, while acknowledging that even with improved formulations, all drugs still have potential adverse effects that require ongoing education and support, particularly for patients who may need lifelong therapy rather than achieving treatment-free remission.

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.

The phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma will continue as planned following an interim review by an independent safety board.

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical cancer.

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

The safety and efficacy of givinostat is being assessed vs hydroxyurea in the phase 3 GIV-IN PV trial.

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication.

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in patients with prostate cancer.

An update to the NCCN guidelines recommends naxitamab-gqgk for adult and pediatric patients with high-risk neuroblastoma.

The FDA has granted accelerated approval to avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.

Panelists discuss how health care providers can promote medication adherence by moving beyond labeling patients as noncompliant, instead investigating root causes such as adverse effects, financial toxicity, or forgetfulness, while emphasizing the importance of building trusting relationships, involving caregivers as accountability partners, and creating personalized solutions that address each patient's specific barriers to maintaining their treatment regimen.

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to tyrosine kinase inhibitor (TKI) therapy can substantially affect molecular response rates, particularly during the critical first year of treatment, which largely determines future outcomes including potential treatment-free remission.

Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.

A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

The FDA granted a complete response letter with no safety concerns for the new drug application for TLX101-CDx’s use in glioma imaging.

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.

Early-phase LUPER trial results suggest the lurbinectedin/pembrolizumab combination may benefit patients with relapsed small cell lung cancer.

Adagrasib shows early signs of activity and tolerability in patients with STK11/KRAS G12C–mutated non–small cell lung cancer.

KN026 plus chemotherapy improved PFS in patients with previously treated HER2-positive advanced gastric or GEJ cancer.

Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.